Bertrand TOMBAL

Université catholique de Louvain

Belgium

Research Interests

Explore related searches

Professors in Belgium

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Collaborators (5)

Oliver Sartor

Tulane University School of Medicine

UNITED STATES

View details

Joe O'Sullivan

The Queen's University Belfast

UNITED KINGDOM

View details

Maha Hussain

UNITED STATES

View details

Ananya Choudhury

The University of Manchester

UNITED KINGDOM

View details

Ilpo Huhtaniemi

Imperial College London

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Bertrand TOMBAL

Research Interests

Explore related searches

Contact this professor

Articles (20)

Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study

Convergence of science, regulations and society in cancer clinical research: A perspective based on the EORTC DE-ESCALATE Study

Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial

Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial

Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer

Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis

Evaluation of clinical risk stratification to determine benefit from long-term versus short-term androgen deprivation in high-risk localized prostate cancer

Fast (< 30 min) “All-in-One” whole-body MRI for TNM staging in high-risk prostate cancer (PCa): Feasibility and comparison to <sup>68</sup>Ga-Prostate Specific Membrane Antigen (PSMA)-PET/CT

Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review

Prostate-specific antigen (PSA) response with darolutamide in metastatic hormone-sensitive prostate cancer and its impact on treatment outcomes in the ARASENS trial: a plain language summary

Systemic Treatment for Biochemical Recurrence of Localized Prostate Cancer: Do Not EMBARK on When, If the Answer Is How

All Biochemical Recurrences Are Equal, but Some Are More Equal than Others

Safety profile of darolutamide versus placebo: a systematic review and meta-analysis

The Loss of Estradiol by Androgen Deprivation in Prostate Cancer Patients Shows the Importance of Estrogens in Males

A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532)

Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study

Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC

Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer

Comparison of <sup>68</sup>Ga-Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography Computed Tomography (PET-CT) and Whole-Body Magnetic Resonance Imaging (WB-MRI) with Diffusion Sequences (DWI) in the Staging of Advanced Prostate Cancer

Collaborators (5)

Oliver Sartor

Joe O'Sullivan

Maha Hussain

Ananya Choudhury

Ilpo Huhtaniemi

Make your next move.

Bertrand TOMBAL

Research Interests

Explore related searches

Contact this professor

Articles (20)

Alkaline phosphatase decline and pain response as predictors of overall survival benefit in patients treated with radium-223: a post hoc analysis of the REASSURE study

Convergence of science, regulations and society in cancer clinical research: A perspective based on the EORTC DE-ESCALATE Study

Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial

Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial

Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer

Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis

Evaluation of clinical risk stratification to determine benefit from long-term versus short-term androgen deprivation in high-risk localized prostate cancer

Fast (&lt; 30 min) “All-in-One” whole-body MRI for TNM staging in high-risk prostate cancer (PCa): Feasibility and comparison to <sup>68</sup>Ga-Prostate Specific Membrane Antigen (PSMA)-PET/CT

Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review

Prostate-specific antigen (PSA) response with darolutamide in metastatic hormone-sensitive prostate cancer and its impact on treatment outcomes in the ARASENS trial: a plain language summary

Systemic Treatment for Biochemical Recurrence of Localized Prostate Cancer: Do Not EMBARK on When, If the Answer Is How

All Biochemical Recurrences Are Equal, but Some Are More Equal than Others

Safety profile of darolutamide versus placebo: a systematic review and meta-analysis

The Loss of Estradiol by Androgen Deprivation in Prostate Cancer Patients Shows the Importance of Estrogens in Males

A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532)

Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

Impact of Relugolix Versus Leuprolide on the Quality of Life of Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study

Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC

Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer

Comparison of <sup>68</sup>Ga-Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography Computed Tomography (PET-CT) and Whole-Body Magnetic Resonance Imaging (WB-MRI) with Diffusion Sequences (DWI) in the Staging of Advanced Prostate Cancer

Collaborators (5)

Oliver Sartor

Joe O'Sullivan

Maha Hussain

Ananya Choudhury

Ilpo Huhtaniemi

Make your next move.

Fast (< 30 min) “All-in-One” whole-body MRI for TNM staging in high-risk prostate cancer (PCa): Feasibility and comparison to <sup>68</sup>Ga-Prostate Specific Membrane Antigen (PSMA)-PET/CT